Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Study Shows that New DNA Test to Identify Down Syndrome in Pregnancy is Ready for Clinical Use

18.10.2011
A new DNA-based prenatal blood test that can strikingly reduce the number of risky diagnostic procedures needed to identify a pregnancy with Down syndrome is ready to be introduced into clinical practice.

The test can be offered as early as 10 weeks of pregnancy to women who have been identified as being at high risk for Down syndrome. These are the results of an international, multicenter study published online today in the journal Genetics in Medicine. The study, the largest and most comprehensive done to date, examined almost 1,700 pregnancies at high risk of chromosomal abnormalities, 212 of which were affected by Down syndrome.

The research was led by Jacob Canick, PhD, and Glenn Palomaki, PhD, of the Division of Medical Screening and Special Testing in the Department of Pathology and Laboratory Medicine at Women & Infants Hospital and The Warren Alpert Medical School of Brown University, and included scientists at Sequenom, Inc. and Sequenom Center for Molecular Medicine, San Diego, CA, and an independent academic laboratory at the University of California at Los Angeles.

The test identified 98.6% of the Down syndrome pregnancies, while only 0.2% of the normal pregnancies were mistakenly called positive. The test rarely failed to provide a clinical interpretation (0.8%). These findings, along with the detailed information learned from testing such a large number of samples, demonstrate that the new test will be highly effective when offered to women considering invasive testing.

“With current screening methods, about one in every 30 women offered a follow-up invasive diagnostic procedure - amniocentesis or chorionic villus sampling (CVS) - will be found to have a pregnancy with Down syndrome. We expect the DNA-based test to more accurately determine which women should be offered invasive diagnostic testing. As a result, most of the pregnancies referred for amniocentesis or CVS will be found to have Down syndrome,” said Dr. Canick.

Dr. Palomaki added, “If this new test is used as we’ve described, nearly all women with a normal pregnancy could avoid an invasive diagnostic procedure and its associated anxiety, cost, and potential for fetal loss.”

Down syndrome, also called trisomy 21, is a chromosomal disorder that includes mental retardation, characteristic facial features, and, often, heart defects, and affects one in 550 babies born each year in the US. Down syndrome occurs when each cell in an individual has three rather than the usual two copies of chromosome number 21. Current prenatal screening tests for Down syndrome combine maternal age with information from the measurement of maternal serum markers and ultrasound markers in the first and second trimesters of pregnancy. While these tests can detect up to 90% of Down syndrome cases, they also incorrectly identify 2% to 5% of normal pregnancies as positive. The new DNA-based test will reduce this “false positive” rate while maintaining the detection rate.

“Prenatal screening and diagnosis of Down syndrome has been part of routine prenatal care for decades, and it is estimated that nearly two-thirds of all pregnant women in the US are currently screened,” said Dr. Canick. “It is possible that with the availability of this new DNA-based test, more women will opt for screening because of the increased safety resulting from far fewer amniocentesis and CVS procedures being performed.” The US Centers for Disease Control and Prevention estimated in 1995 that about one in every 200 invasive diagnostic procedures will cause a pregnancy miscarriage.

This industry-sponsored project, awarded to Drs. Canick and Palomaki and Women & Infants Hospital in 2008, enrolled 4,500 women at 27 prenatal diagnostic centers throughout the world. Women & Infants also served as one of the enrollment centers under the direction of maternal-fetal medicine specialist and director of Perinatal Genetics, Barbara O’Brien, MD.

“Screening tests, by their nature, do not diagnose, but rather offer information about the chances that a pregnancy may be affected by a genetic abnormality. For years we have relied on screening tests that have had a fairly significant false positive rate because that was the best screening available,” said Dr. O’Brien. “But having access to a DNA-based test that can be done early in pregnancy will give us more information so that we can better guide which patients should consider diagnostic testing.”

Women & Infants Hospital has been an international center for prenatal screening research. For more than three decades, Drs. Canick and Palomaki have collaborated with others in developing and improving screening tests for Down syndrome and other fetal abnormalities. In 1988, Drs. Canick and Palomaki were involved in the development of triple marker screening. The team was able to convert its findings into prenatal screening tests now used throughout the world. Dr. Canick’s lab in 1998 was the first in the US to offer quad marker screening and in the past decade was the laboratory center for the National Institute of Health (NIH) funded FASTER Trial which compared first and second trimester screening.

It was announced today that one version of this laboratory-developed test, MaterniT21, has been validated through clinical studies and is now available through the Sequenom Center for Molecular Medicine, a CLIA-certified and CAP-accredited laboratory. Harry F. Hixson Jr., PhD, chairman and CEO of Sequenom, Inc., said, “We have been fortunate to partner in the clinical study and are proud to offer the service to assist specialists and high-risk patients in making more informed decisions about their pregnancy.”

About Women & Infants Hospital
Women & Infants Hospital of Rhode Island, a Care New England hospital, is one of the nation’s leading specialty hospitals for women and newborns. A U.S.News Best Hospital in Gynecology and Best Children’s Hospital in Neonatology, Women & Infants was ranked number one in the Providence metro area and a top-performer in cancer, and has achieved a 5-star rating in Maternity Care for 2011 from HealthGrades. The primary teaching affiliate of The Warren Alpert Medical School of Brown University for obstetrics, gynecology and newborn pediatrics, as well as a number of specialized programs in women’s medicine, Women & Infants is the seventh largest obstetrical service in the country with more than 8,500 deliveries per year. In 2009, Women & Infants opened the country’s largest, single-family room neonatal intensive care unit.

New England’s premier hospital for women and newborns, Women & Infants and Brown offer fellowship programs in gynecologic oncology, maternal-fetal medicine, urogynecology and reconstructive pelvic surgery, neonatal-perinatal medicine, pediatric and perinatal pathology, gynecologic pathology and cytopathology, and reproductive endocrinology and infertility. It is home to the nation’s only mother-baby perinatal psychiatric partial hospital, as well as the nation’s only fellowship program in obstetric medicine.

Women & Infants has been designated as a Breast Center of Excellence from the American College of Radiography; a Center for In Vitro Maturation Excellence by SAGE In Vitro Fertilization; a Center of Biomedical Research Excellence by the National Institutes of Health; and a Neonatal Resource Services Center of Excellence. It is one of the largest and most prestigious research facilities in high risk and normal obstetrics, gynecology and newborn pediatrics in the nation, and is a member of the National Cancer Institute’s Gynecologic Oncology Group.

About Brown University
Founded in 1764 and a member of the Ivy League, Brown University is globally acclaimed for its culture of independent thinking and academic excellence. For decades, Brown faculty and students have pursued multidisciplinary research in areas such as brain science, digital humanities, nanoscience, and population studies. Since 2002, under a strategic plan, Brown has invested significantly in research, resulting in a 65 percent gain in external research awards, a 33 percent increase in graduate enrollment, and a rise in total faculty of 16 percent.

How DNA testing for Down syndrome works in practice

As an example of how the new test might be used in practice, consider a group of 10,000 pregnant women. There will be 20 cases of Down syndrome in this group. If all 10,000 undergo the current screening tests, 500 are identified as screen positive and, in the present system, all 500 are offered invasive diagnostic testing for chromosome analysis. Eighteen of the 20 Down syndrome cases will be among the 500 women having an invasive procedure, and all 18 will be identified. However, all 482 of these 500 women who have a normal pregnancy underwent an unnecessary invasive procedure. Two procedure-related losses would be expected among these 482 women.

If, instead, the new DNA-based test were offered to the 500 screen positive women, and those found to be positive by the DNA-based test (or the test failed) went on to invasive testing, only the 18 affected pregnancies plus five of the normal pregnancies would now be offered an invasive procedure. All 18 Down syndrome cases would still be correctly identified. The five unaffected pregnancies would be correctly identified, and 477 unnecessary invasive procedures would have been avoided, along with the two procedure-related losses.

Amy Blustein | EurekAlert!
Further information:
http://www.wihri.org

More articles from Studies and Analyses:

nachricht Drone vs. truck deliveries: Which create less carbon pollution?
31.05.2017 | University of Washington

nachricht New study: How does Europe become a leading player for software and IT services?
03.04.2017 | Fraunhofer-Institut für System- und Innovationsforschung (ISI)

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Can we see monkeys from space? Emerging technologies to map biodiversity

An international team of scientists has proposed a new multi-disciplinary approach in which an array of new technologies will allow us to map biodiversity and the risks that wildlife is facing at the scale of whole landscapes. The findings are published in Nature Ecology and Evolution. This international research is led by the Kunming Institute of Zoology from China, University of East Anglia, University of Leicester and the Leibniz Institute for Zoo and Wildlife Research.

Using a combination of satellite and ground data, the team proposes that it is now possible to map biodiversity with an accuracy that has not been previously...

Im Focus: Climate satellite: Tracking methane with robust laser technology

Heatwaves in the Arctic, longer periods of vegetation in Europe, severe floods in West Africa – starting in 2021, scientists want to explore the emissions of the greenhouse gas methane with the German-French satellite MERLIN. This is made possible by a new robust laser system of the Fraunhofer Institute for Laser Technology ILT in Aachen, which achieves unprecedented measurement accuracy.

Methane is primarily the result of the decomposition of organic matter. The gas has a 25 times greater warming potential than carbon dioxide, but is not as...

Im Focus: How protons move through a fuel cell

Hydrogen is regarded as the energy source of the future: It is produced with solar power and can be used to generate heat and electricity in fuel cells. Empa researchers have now succeeded in decoding the movement of hydrogen ions in crystals – a key step towards more efficient energy conversion in the hydrogen industry of tomorrow.

As charge carriers, electrons and ions play the leading role in electrochemical energy storage devices and converters such as batteries and fuel cells. Proton...

Im Focus: A unique data centre for cosmological simulations

Scientists from the Excellence Cluster Universe at the Ludwig-Maximilians-Universität Munich have establised "Cosmowebportal", a unique data centre for cosmological simulations located at the Leibniz Supercomputing Centre (LRZ) of the Bavarian Academy of Sciences. The complete results of a series of large hydrodynamical cosmological simulations are available, with data volumes typically exceeding several hundred terabytes. Scientists worldwide can interactively explore these complex simulations via a web interface and directly access the results.

With current telescopes, scientists can observe our Universe’s galaxies and galaxy clusters and their distribution along an invisible cosmic web. From the...

Im Focus: Scientists develop molecular thermometer for contactless measurement using infrared light

Temperature measurements possible even on the smallest scale / Molecular ruby for use in material sciences, biology, and medicine

Chemists at Johannes Gutenberg University Mainz (JGU) in cooperation with researchers of the German Federal Institute for Materials Research and Testing (BAM)...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Plants are networkers

19.06.2017 | Event News

Digital Survival Training for Executives

13.06.2017 | Event News

Global Learning Council Summit 2017

13.06.2017 | Event News

 
Latest News

Study shines light on brain cells that coordinate movement

26.06.2017 | Life Sciences

Smooth propagation of spin waves using gold

26.06.2017 | Physics and Astronomy

Switchable DNA mini-machines store information

26.06.2017 | Information Technology

VideoLinks
B2B-VideoLinks
More VideoLinks >>>